<i>Lolium perenne</i> peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Pediatric Allergy and Immunology, and Clinical and Translational Allergy. EAACI's major goals include supporting the promotion of health, in which the prevention of allergy and asthma plays a critical role, and disseminating the knowledge of allergic disease to all stakeholders. In 2018, the remarkable progress in the identification of basic mechanisms of allergic and respiratory diseases as well as the translation of these findings into clinical practice were observed. Last year's highlights include publication of EAACI guidelines for allergen immunotherapy, many EAACI Position Papers covering important aspects for the specialty, better understanding of molecular and cellular mechanisms, identification of biomarkers for disease prediction and progress monitoring, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, introduction of new drugs to the clinics, recently completed phase three clinical studies, and publication of a large number of allergen immunotherapy studies and meta‐analyses.

Section: Allergen Immunotherapy (Ait)mentioning

confidence: 99%

Section: Allerg En Immunother Apy ( Ait )mentioning

confidence: 99%

Highlights and recent developments in airway diseases in EAACI journals (2018)

Bousquet

Akdiş

Grattan

et al. 2019

“…Modified allergens such as recombinant allergens, allergoids, and allergen peptides have also recently been developed for use in AIT. Mösges et al have demonstrated that a novel SCIT formulation containing Lolium perenne (perennial ryegrass) peptides can be administrated at higher doses for the relatively short duration of 3 weeks to improve tolerance and significantly increase the levels of specific IgG4 antibodies. These authors further demonstrated that L perenne peptide immunotherapy is not only well‐tolerated, but also able to elicit protective B‐cell responses in seasonal AR patients .…”

Section: Treatmentmentioning

confidence: 99%

“…Mösges et al have demonstrated that a novel SCIT formulation containing Lolium perenne (perennial ryegrass) peptides can be administrated at higher doses for the relatively short duration of 3 weeks to improve tolerance and significantly increase the levels of specific IgG4 antibodies. These authors further demonstrated that L perenne peptide immunotherapy is not only well‐tolerated, but also able to elicit protective B‐cell responses in seasonal AR patients . Indeed, other studies have indicated that recombinant B‐cell epitopes and continuous overlapping peptides are also well‐tolerated in AIT.…”

Section: Treatmentmentioning

confidence: 99%

Recent developments and highlights in allergic rhinitis

Meng

Wang

Zhang

2019

124

105

Allergic rhinitis (AR) is a disease with high prevalence all over the world and therefore needs to be thoroughly investigated and treated accordingly. The mechanisms underlying the pathology and treatment of AR have been widely studied, but many aspects remain unclear and warrant further investigations. This review presents an overview of recently published papers highlighting the risk factors, mechanisms, and treatment of AR. Additionally, recent studies discussing the role of single nucleotide polymorphism, DNA methylation, regulatory B cells, group 2 innate lymphoid cells, immunotherapy, and biologics in AR are also covered. K E Y W O R D Sallergic rhinitis, biologics, epigenetics, risk factors, treatment | 2321 MENG Et al.

“…18,19 In addition, immunotherapy with allergen-derived T-cell epitope-based peptides is being trialled in intradermal and subcutaneous formulations. 20,21 These peptides do not invoke IgE responses and mitigate the risk of anaphylaxis, but target the specific, disease-driving T cells. Similarly, the use of hypoallergenic but T-cellreactive allergen peptides derived by proteolytic hydrolysis for grass pollen allergy treatment also shows promise.…”

Section: Allergen Immunotherapy: a Prototype Of Precision Medicinementioning

confidence: 99%

Recent developments and highlights in immune monitoring of allergen immunotherapy

Zelm

McKenzie

Varese

et al. 2019

Allergic diseases are the most common chronic immune-mediated disorders and can manifest with an enormous diversity in clinical severity and symptoms. Underlying mechanisms for the adverse immune response to allergens and its downregulation by treatment are still being revealed. As a result, there have been, and still are, major challenges in diagnosis, prediction of disease progression/evolution and treatment.Currently, the only corrective treatment available is allergen immunotherapy (AIT).AIT modifies the immune response through long-term repeated exposure to defined doses of allergen. However, as the treatment usually needs to be continued for several years to be effective, and can be accompanied by adverse reactions, many patients face difficulties completing their schedule. Long-term therapy also potentially incurs high costs. Therefore, there is a great need for objective markers to predict or to monitor individual patient's beneficial changes in immune response during therapy so that efficacy can be identified as early as possible. In this review, we specifically address recent technical developments that have generated new insights into allergic disease pathogenesis, and how these could potentially be translated into routine laboratory assays for disease monitoring during AIT that are relatively inexpensive, robust and scalable. K E Y W O R D Sallergen immunotherapy, allergy, biomarker, immune monitoring | 2343 ZELM Et aL.